Diabetes Devices and Drugs: North America Guides Global Market at a 5.9% CAGR from 2013 to 2019 - Transparency Market Research

The global diabetes devices and drugs market is likely to grow from US$54.04 billion in 2012 to US$83.0 billion in 2019.The diabetes devices market is bifurcated into insulin delivery devices and diabetes monitoring and diagnostic devices. The major diabetes monitoring and diagnostic devices include glucose test strips, analog glucose meter, and continuous glucose monitoring devices, and lancets and lancing devices. By the end of 2019, test strips are anticipated to be the leading segment while continuous glucose monitoring devices will be the most rapidly growing segment. Insulin delivery devices include insulin pens, insulin pumps, insulin syringes, and insulin injectors. Insulin pens, followed by syringes, formed the largest segments in 2012.

On the basis of therapy, the diabetes drugs market is segmented into oral anti-diabetes drugs class, insulin, and non-insulin injectable anti-diabetes drugs. The various insulin derivatives include premixed insulin, rapid-acting insulin, short-acting insulin, long-acting insulin, and intermediate-acting insulin. With a 42.77% share, long-acting insulin derivatives held the majority in 2012 and are expected to record the highest CAGR by 2019. The oral anti-diabetes drugs class comprises Thiazolidinediones, SGLT-2 inhibitors, Sulphonylureas, DPP-4 inhibitors, Meglitinides, Biguanides, and Alpha-glucosidase inhibitors. Registering an impressive CAGR of 76.8% from 2013 to 2019, SGLT-2 inhibitors are expected to form the fastest growing segment. Non-insulin injectable anti-diabetes drugs include GLP-1 analogs, which are also anticipated to develop at a strong pace over the course of the forecast period. 

The global diabetes devices and drugs market covers four key regions: North America, Europe, Asia Pacific, and Rest of the World. Rise in diabetic population and growing demand for technologically-advanced devices and high-quality drugs has made North America the leading market for diabetes devices and drugs. However, Asia Pacific has been identified as the fastest developing regional segment from 2013 to 2019. This market is fueled by rise in diabetic population, increasing awareness about the management and self-monitoring of diabetes, hike in medical expenditure, and growing penetration of healthcare technology. 

Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14

The competitive landscape of the global diabetes devices and drugs market consists of numerous small and large players. Some of the dominating participants of the diabetes devices and drugs market are AstraZeneca plc, DexCom, Inc., Johnson & Johnson, Becton, Dickinson & Company, Merck & Co., Inc., Eli Lilly and Company, Bayer HealthCare AG, Lupin Limited, B. Braun Melsungen AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, Novartis International AG, Takeda Pharmaceutical Company Limited, Sanofi, Abbott Laboratories, Inc., Medtronic, Inc., and Novo Nordisk A/S. 

Browse the full Diabetes Devices and Drugs Market (Devices: Diagnostic & Monitoring and Insulin Delivery Devices, Drugs: Insulin Derivatives, GLP-1 and OADs) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 report at http://www.transparencymarketresearch.com/diabetes-devices-market.html

Global Diabetes Devices Market, by Devices

• Diabetes Monitoring and diagnostic devices
  • Analog glucose meter
  • Glucose Test strips
  • Lancets and Lancing devices
  • Continuous glucose monitoring devices
  • Others
• Insulin Delivery Devices
  • Insulin Syringes
  • Insulin Pens
  • Insulin Pumps
  • Insulin Injectors

Global Diabetes Drugs Market, by Therapy

• Insulin
  • Short-acting insulin derivatives
  • Intermediate-acting insulin derivatives
  • Long-acting insulin derivatives
  • Rapid-acting insulin derivatives
  • Premixed insulin derivatives
• Oral anti-diabetes drugs class
  • Sulphonylureas
  • Biguanides
  • Meglitinides
  • Thiazolidinediones
  • Alpha-glucosidase inhibitors
  • DPP-4 inhibitors
  • SGLT-2 inhibitors
• Non-insulin injectable anti-diabetes drugs
  • GLP-1 analogs

Global Diabetes Drugs Market, by Geography

• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Contacts

Mr. Nachiket

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/